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A reliable, accurate, noninvasive method for identifying
patients with GERD in the primary care setting is needed.
A population-screening instrument may assist managed
care organizations and clinicians to identify candidates
for disease management, or quality improvement pro-
grams. OBJECTIVE: To develop and validate a GERD
screening instrument. METHODS: A screening instru-
ment containing 10 questions was developed based on lit-
erature review and expert opinion. Categorical and con-
tinuous scoring methods with and without medication
use were identified a priori. Using telephone interview in
a medical group, we identified and enrolled 100 subjects
with a history of GERD-like symptoms and 100 controls.
Each subject completed the screening instrument, a vali-
dated gastrointestinal symptom questionnaire (DHSI),
and was evaluated independently by 2 gastroenterologists
using a structured format. The gold standard was defined
as patients who required an intervention and who had
physician agreement that their symptoms were consistent
with GERD. RESULTS: 70 subjects were classified as
GERD using the gold standard (kappa  0.79). Using a
continuous measure of GERD symptoms, including fre-
quency, severity, and type of medication use as the scor-
ing method (total score range 0–29), an area under the
receiver operator characteristic curve (ROC) of 0.89
(95% CI 0.84–0.94) was observed. Using a cutoff of 9
points, this measure is 83% sensitive and 82% specific.
Using a cutoff of 12 points, this measure is 65% sensi-
tive and 92% specific. Compared to the gold standard,
the DHSI GERD subscale has a ROC of 0.89 (95% CI
0.84–0.94). The screening instrument was highly corre-
lated with the DHSI GERD subscale, r  0.74 (95% CI
0.67–0.80; P  0.0001). CONCLUSIONS: The screen-
ing instrument appears to have construct, convergent and
predictive validity. It is shorter than existing validated in-
struments, practical and easily administered. This may
serve as a valuable case-finding instrument in primary
care and managed care organizations.
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There are three licensed alternatives for managing ad-
vanced breast cancer (ABC) patients in the UK, but they
have not been directly compared in clinical studies. OB-
JECTIVE: To capture the costs and quality of life (QoL)
related outcomes for ABC patients managed with doce-
taxel (DOC) in comparison to vinorelbine (VIN) and pac-
litaxel (PAC). METHODS: An updated version of the
Hutton et al. (Pharmacoeconomics 9 Suppl 2, 1996)
model was used to simulate the experiences (associated
costs and outcomes) of patients undergoing treatment for
ABC, from the onset of salvage chemotherapy to death.
Published clinical trials were used to establish response
rate, time to progression, median survival, rate of grade
four febrile neutropenia, and toxicity rate related to che-
motherapeutic agent. QoL utility scores were obtained
from oncology nurses. Costs were taken from published
sources and reflect the UK National Health Service and
were discounted at 6%. RESULTS: The average patient
costs were £4268 for VIN, £7817 for DOC and £7645
for PAC. The estimated Quality Adjusted Life Year (QALY)
values were 0.48 for VIN, 0.73 for DOC and 0.65 for
PAC; an additional 91 days of good quality life for DOC
versus VIN and an additional 29 days of good quality life
versus PAC. The incremental cost per QALY for DOC
was £14,500 compared with VIN and £1,990 compared
with PAC. Various sensitivity analyses were undertaken
and did not greatly change the findings. The cost-effec-
tiveness ratios are within the range of generally accept-
able technologies. CONCLUSION: Patients managed
with DOC have improved QoL in comparison to these
alternative chemotherapies and a longer median survival.
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Abstracts
 
In Hong Kong, the government subsidizes over 90% of
the medical costs of a patient admitted to a public hospi-
tal. Economic information on new drugs is required for
formulary consideration. Ceftazidime is reserved for the
treatment of severe nosocomial infection. Trovafloxacin,
a new antibiotic introduced to Hong Kong, is a potential
alternative of ceftazidime. OBJECTIVE: To compare the
cost-effectiveness of trovafloxacin with ceftazidime in
nosocomial pneumonia (NP) from a hospital perspective.
METHODS: A decision-analytic modeling method was
employed. Clinical data used were adopted from a ran-
domized clinical trial conducted overseas comparing the
two antibiotics in the treatment of NP together with con-
sultation of a local expert panel. Patients either received
IV alatrofloxacin (injectable form of trovafloxacin) 300
mg every 24 hrs or IV ceftazidime 1 g q8h. The success
rate of alatrofloxacin was 74% and 70% for ceftazidime.
Median duration of IV therapy was 6 and 7 days respec-
tively. Alatrofloxacin and ceftazidime were converted to
trovafloxacin PO 300 mg qd and ciprofloxacin PO 750
mg bid, respectively, to complete a 14-day treatment. In
the event of treatment failure, IV gentamicin 80mg q8h
would be added. Economic data were obtained from the
finance office of the authority concerned. Only direct
medical costs were included in the analysis. Sensitivity
analysis was performed to check the robustness of the re-
sults. RESULTS: The direct cost per patient treated was
HK $28,332 in the trovafloxacin group compared with
HK $31,389 for ceftazidime. CONCLUSION: Alatro-
floxacin/ trovafloxacin therapy appears to be slightly more
cost-effective than ceftazidime in the treatment of NP.
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OBJECTIVE:
 
 Economic analysis comparing Coumadin
(C) and generic warfarins with a range of bioavailabilities
in a population of atrial fibrillation patients from a pro-
vincial government payer perspective over one year.
 
METHODS:
 
 Cost-minimization and cost-effectiveness anal-
yses were conducted. A Markov decision analytic model
evaluated generic warfarin products with bioavailabilities
of 
 

 
2% to 
 

 
15% and 
 

 
20% to 
 

 
25% different from
C. Three clinical scenarios were simulated: (1) C only for
a year (2) generic warfarin only for a year and (3) two ge-
neric agents alternating monthly for a year. Bioavailabili-
ties for generic products were translated into INRs.
Costs: Direct medical (hospital, drug, laboratory, physi-
cian fees). Clinical event: medical literature, Bleeds and
Clots. RESULTS: The average total expected annual cost
for C was $1751. The average expected costs for all ge-
neric agents ranged from $1711 to $2154. In the incre-
mental analysis, generic warfarins, one agent only, pre-
scribed for one year, were dominant (i.e., cheaper) than
C. C was dominant when compared to strategies involv-
ing alternating between generic products for a year. Devia-
tion from C for Clots and Bleeds occurred when bioavail-
abilities were 10% for alternating generic regimens.
Incremental cost-effective ratios ranged from $7000–
$32000 per Clot avoided and $30000–$38000 for Bleed
avoided. CONCLUSIONS: Single generic warfarins with
bioavailabilities similar to C had cost savings. Regimens
involving alternating between two generic warfarins that
differ by 20% and 25% associated with excessive costs.
This may lead to additional INR monitoring, dose adjust-
ments and adverse clinical outcomes.
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OBJECTIVES:
 
 We compared healthcare resource utiliza-
tion (hospitalizations, physician visits, prescriptions) be-
tween users of pravastatin, lovastatin, and simvastatin.
METHODS: Manitoba’s Health Research Database
identified statin users between 95/1/1 and 98/3/31. Inci-
dent users received a first prescription for a statin after
95/4/30; prevalent users had a prescription before 95/5/1.
Statin ‘interacters’ were on 1 prescription for an inter-
acting drug while on a statin (Group A drug’s levels were
increased; Group B drugs increased levels of statins). Wil-
coxon’s ranksum test analyzed differences by statin on
healthcare resource use. RESULTS: 24,555 statin users
(15,148 incident and 9,407 prevalent) were identified.
19,850 (80.8%) individuals took one statin; 16.7% took
two statins. Most common Group A interactions were
with warfarin (9.7%), amitriptyline (4.4%), and imi-
pramine (4.4%); in Group B, itraconazole (10.8%), ome-
prazole (6.7%), and clarithromycin (4.4%) were the
most common. Statin interacters consumed significantly
more healthcare resources than did noninteracters for
both incident and prevalent analyses. New pravastatin
users taking interacting drugs had on average signifi-
cantly fewer hospitalizations (0.85) and physician visits
(19.33), and lower healthcare costs ($3,954) compared
to new users of lovastatin (1.21, 22.03, $5,559) and sim-
vastatin (1.07, 21.21, $4,734). The comparison of preva-
